EyePoint, Inc. - Common Stock (EYPT)

As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for small-cap stocks, has notably outperformed the tech-heavy S&P 500 and the Nasdaq Composite. This early-January

As the sun rises on January 1, 2026, the financial landscape is witnessing a profound shift that many analysts have anticipated for years: the definitive return of the U.S. small-cap sector. After a long period of living in the shadow of "Magnificent Seven" mega-caps, smaller domestic companies are finally

As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P 500 (INDEXSP: .INX) is finishing the year near the psychological 7,000 mark, a milestone that

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

EyePoint (EYPT) Q3 2025 Earnings Call Transcript

EyePoint Pharmaceuticals stock falls after Q3 2025 earnings miss estimates. Despite the financial setback, its key DURAVYU trials for wet AMD are fully enrolled and on track for 2026 data.

EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.

EyePoint Pharmaceuticals (EYPT) Q2 2025 earnings miss estimates with $5.33M revenue and -$0.85 EPS, sparking a 4.5% pre-market drop. Clinical progress in DURAVYU Phase 3 trial offers hope amid financial setbacks.

Momentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth.

Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.